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Hypertension and Stroke
MICHAEL D. CRESSMAN, DO, RAY W. GIFFORD, Jr., MD, FACC
Cleveland, OhIO
The longitudinal analysis of the adult population of Fra-
mingham, Massachusetts has clarified the pivotal role
of hypertension in the epidemiology of stroke. Stroke
incidence increases in men and women as arterial blood
pressure, either systolic or diastolic, increases. Isolated
systolic hypertension increases the risk of stroke in the
elderly. Successful antihypertensive therapy decreases
stroke incidence in asymptomatic persons, hypertensive
patients with transient ischemic attacks and survivors
of hypertensive stroke. A stepped care approach to anti-
hypertensive therapy utilizing diuretic drugs, antiad-
renergic agents and vasodilators is well tolerated in the
vast majority of patients with established cerebrovas-
cular disease. Agents with a propensity to cause ortho-
Stroke is a major contributor to physical and psychologic
morbidity, and is ranked third as a cause of death in the
United States. Of the risk factors for stroke, hypertension
appears to be the most important and the most treatable.
Hypertension is associated with an increased incidence of
atherothrombotic and hemorrhagic stroke in patients of both
sexes at all ages (I).
Effective antihypertensive therapy undoubtedly contrib-
utes to the sharp decline in the incidence of fatal stroke in
the United States (2,3). We review the epidemiologic evi-
dence that links hypertension to stroke, the impact of anti-
hypertensive therapy on stroke prevention and guidelines
for the use of antihypertensive agents in patients with es-
tablished cerebrovascular disease.
Hypertension and Epidemiology of Stroke
The prospective, longitudinal study of the adult popu-
lation of Framingham, Massachusetts has clarified the role
of hypertension as a precursor to stroke (I). Hypertension
was defined as a blood pressure of 160/95 mm Hg or greater
on two recordings at any clinic visit. Isolated systolic hy-
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static hypotension should be avoided. Reduction of blood
pressure should be gradual with dose increments at in-
tervals of 6 to 8 weeks. Mild hypertension may be left
untreated during the acute phase of atherothrombotic
brain infarction. A trial of blood pressure reduction with
sodium nitroprusside to normotensive or mildly hypo-
tensive levels is indicated in patients with acute intra-
cranial hemorrhage. Ifneurologic deterioration occurs,
the infusion rate of sodium nitroprusside can be reduced
and blood pressure will rapidly rise. Successful man-
agement of hypertension has undoubtedly contributed
to the decreasing death rate from stroke in the United
States.
pertension was defined as a systolic pressure of 160 mm Hg
or greater when the diastolic pressure was less than 95 mm
Hg. Patients were considered "normotensive" if the blood
pressure was consistently less than 140/90 mm Hg and to
have "borderline" hypertension when the blood pressure
was greater than 140/90 mm Hg but less than 160/95 mm
Hg. After 14 years of follow-up, it was apparent that hy-
pertensive patients were at risk for all of the major athero-
thrombotic diseases, but the risk of stroke and congestive
heart failure was particularly striking. Hypertension was
associated with an increased incidence of both hemorrhagic
and nonhemorrhagic stroke independent of other risk factors.
Role of systolic hypertension. The average annual in-
cidence rate of stroke after 18 years of follow-up was found
to be directly related to the antecedent blood pressure status
for both men and women in all age groups (4). Although
there was a correlation between systolic and diastolic blood
pressure in this group of patients, systolic blood pressure
was more closely correlated with stroke incidence than was
diastolic blood pressure, pulse pressure or mean arterial
pressure. As systolic blood pressure increased, so did the
incidence of stroke so that no safe level of systolic blood
pressure could be determined. The incidence of athero-
thrombotic brain infarction was three to four times greater
when systolic blood pressure was 160 mm Hg than when
systolic pressure was 130 mm Hg.
Isolated systolic hypertension increases the risk of stroke
(5). Data from the Chicago Stroke Study have shown that
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in elderly patients (aged 65 to 74 years) whose diastolic
blood pressure is less than 80 mm Hg, the 3 year incidence
of stroke increases from 42 per I ,000 population when sys-
tolic blood pressure is less than 140 mm Hg to 110 per
1,000 population when systolic blood pressure is 160 mm
Hg or greater.
Is systolic hypertension an independent risk factor for
stroke? The prevalence of isolated systolic hypertension
increases with age , presumably because of the loss of com-
pliance in rigid atherosclerotic arterie s. It has been assumed
by some that the greater incidence of stroke in the elderly
population with systolic hypertension is merely a reflection
of the underlying arterial disease with systolic hypertension
serving as a marker for arterial rigidity rather than an in-
dependent risk factor for stroke (6). If this were the case,
reducing the elevated systolic blood pressure would not be
expected to decrease the incidence of stroke. Lax et al. (7)
noted that the dicrotic notch on a peripheral pulse wave
tracing disappears when vessels are atherosclerotic. Pulse
wave tracings were obtained in 1,825 patients with systolic
hypertension (systolic blood pressure greater than 160 mm
Hg with diastolic blood pressure less that 95 mm Hg) in the
Framingham study (8). When standardized logistic coeffi-
cients for the regression of stroke incidence were used ,
systolic hypertension emerged as a significant risk factor for
stroke independent of age, diastolic blood pressure or pulse
wave configuration , suggesting that reduction of systolic
blood pressure might decrease stroke incidence in this el-
derly population . However, no controlled longitudinal stud-
ies of antihypertensive therapy in patients with isolated sys-
tolic hypertension are available to support or refute this
notion (6).
Antihypertensive Therapy and Primary
Stroke Prevention
Hypertension and Stroke
Veterans Administration Cooperative Study, The value
of antihypertensive therapy in the primary prevention of
stroke has been established in several controlled, prospec-
tive therapeutic trials (Table I). In 1963. the Veterans
Admini stration Cooperative Study Group (9) initiated a trial
of antihypertensive agents (hydrochlorothiazide , reserpine
and hydralazine) in patients with a diastolic blood pressure
of 90 to 129 mm Hg. One hundred forty-three men with
moderately severe hypertension (diastolic blood pressure
lIS to 129 mm Hg) were randomized to placebo or active
drug treatment and followed up bimonthly for an average
of 18 months. This study was terminated prematurely be-
cause of the large incidence of major hypertensive compli-
cations in the placebo group. Of 70 patients receiving pla-
cebo, 3 had cerebral infarction, I had cerebral hemorrhage
and I had recurrent transient ischemic attacks . Diastol ic
blood pressure decreased by an average of 30 mm Hg in
the actively treated patient s. Of the 73 activel y treated pa-
tients. I had a nonfatal cerebral thrombosis from which he
recovered completely. Antihypertensive therapy also ap-
peared to be effective in preventing stroke in patients with
milder degrees of hypertension (10). In the Veterans Admin-
istration study, 380 men with diastolic blood pressures be-
tween 90 and 114 mm Hg were followed up for an average
of 3.3 years. Fatal or nonfatal stroke occurred in 10.3% of
the placebo group and 2.7 % of the drug-treated group.
Australian controlled therapeutic trial. The National
Heart Foundation of Australia conducted a controlled ther-
apeutic trial of antihypertensive therapy in 3.427 men and
women with mild hypertension (diastolic blood pressure 95
to 109 mm Hg and systolic blood pressure less than 200
mm Hg) (Table I) (II). Drug treatment involved the se-
quential administration of diuretic drugs, methyldopa or
beta-receptor blocking agents and hydralazine or c1onidine.
The goal of active drug treatment was to reduce diastolic
blood pressure to 90 mm Hg or less in the first year and to
less than 80 mm Hg in the second year, although the latter
goal was not achieved . The trial ended in 1979 when sta-
tistical analysis showed a significantly greater incidence of
ischemic cerebral and card iovascular events in the placebo
group . Of 3.427 patients, 2,218 continued their trial regimen
until the trial was terminated or a trial end point was reached.
The incidence of transient ischemic attack s, fatal stroke and
nonfatal stroke was reduced by 50% in this "on treatment"
group .
Systematic stepped care approach. The findings of the
Hypertension Detection and FOllOW-Up Program (HDFP)
Cooperative Study Group were recently reported (12). This
study was designed to determine the efficacy of a systematic
stepped care approach to antihypertensive therapy compared
with treatment in a group referred to the usual sources of
care in the community for a cohort of more than 10,000
hypertensive patients . The stepped care approach involved
the sequential use of oral diuretic drugs, adrenergic blocking
agents and vasodilators as needed to achieve adequate blood
pressure control. Goal diastolic blood pressure was defined
as 90 mm Hg or less for those patient s with a diastolic blood
pressure of 100 mm Hg or greater and for patients already
receiving antihypertensive medications, or at least a 10 mm
Hg decrease in those entering with a diastolic blood pressure
of 90 to 99 mm Hg. Goal blood pressure control was achieved
more frequentl y in the group receiving stepped care than in
the group referred for care in each of the 5 years of follow-
up for whites and blacks of both sexes. Fatal and nonfatal
stroke rate was reduced in the stepped care group regardless
of race , sex or severity of hyperten sion, the overall 5 year
stroke incidence being 2.9/1 00 participants in the referred
care group compared with 1.9/ I00 participants in the stepped
care group (Table 2). The 45% reduction in stroke incidence
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Table 1. Fatal and Nonfatal Stroke Incidence (per 100 population) in Controlled Trials of Antihypertensive Therapy
VA Study (9) VA Study (10) Australian Trial*( II)
(DBP 115-129 mm Hg) (DBP 90-114 mm Hg) (DBP 95-109 mm Hg)
Average length offollow-up (yr)
Placebo 1.3 3 3 3.0
Active drug 1.7 32 3. 1
Patients (no.)
Placebo 70 194 1080
Active 73 186 1138
Fatal strokest
Placebo 0 36 0 4
Active 0 05 02
Nonfatal strokesr
Placebo 4.3 6.7 1.2
Active 1.4 22 0.6
Total strokesr
Placebo 4.3 10.3 1.6
Active 1.4 2.7 0.8
"Includes only the 2.218 patients In the "on treatment" analysis. tValues are per 100 population
DBP = diastolic blood pressure. VA = Veterans Administration
for patients aged 60 through 69 years further supports the
notion that antihypertensive therapy is beneficial even in
elderly patients.
Hypertension and Transient Ischemic Attacks
Role of hypertension in recur rence of attacks. There
is no longer any question that control of hypertension will
decrease the incidence of stroke in asymptomatic patients.
There is still some reluctance to treat hypertension in patients
with transient ischemic attacks. Whistnant et al. (13) fol-
lowed up 199patients from Rochester, Minnesota after their
first carotid or vertebral-basilar transient ischemic attack to
assess the benefits and risks of anticoagulant therapy and to
define the effect of hypertension on survival and the prob-
ability of stroke. Multivariate methods of analysis were used
to identify risk factors for stroke within the first year after
an initial transient ischemic attack. This analysis included
anticoagulant therapy, diastolic blood pressure at the time
of the initial transient ischemic attack and a history of car-
diac disorders such as angina pectoris, myocardial infarc-
tion. valvular heart disease, congestive heart failure and
cardiac arrhythmias. Diastolic blood pressure was shown to
be the most significant of these variables. Approximately
40% of the patients with diastolic blood pressures exceeding
105 mm Hg had a stroke within I year of their initial tran-
sient ischemic attack. The probability of stroke in the first
year was less than 15 % for patients with diastolic blood
pressures less than 105 mm Hg. Patients receiving antihy-
pertensive therapy had a 1 year incidence of stroke which
was slightly less than that of normotensive or mildly hy-
pertensive patients. These trends in stroke incidence were
apparent throughout the 5 year period of observation. The
probability of stroke in this 5 year period was roughly 55%
for patients with a diastolic blood pressure exceeding 105
mm Hg, 30% for patients with a diastolic blood pressure
of 105 mm Hg or less, and 20% for patients receiving
antihypertensive therapy.
The large incidence of stroke in patients with transient
ischemic attacks has led to a more aggressive approach to
medical and surgical management . Patients with carotid
system transient ischemic attacks and localized extracranial
atherosclerotic obstruction or plaque formation appear to
benefit from carotid endarterectomy (14). Antiplatelet and
anticoagulant agents have also been shown to decrease the
incidence of transient ischemic attack and stroke in clinical
Table 2. Stroke Incidence (per 100 population) for the Stepped
Care (SC) and Referred Care (RC) Groups by Age. Race, Sex
and Diastolic Blood Pressure (DBP)
%L
SC RC by SC
Men
While 1.5 2.5 40 0
Black 3. 1 37 162
Women
While 1.6 2.3 30.4
Black 1.8 3.3 45 5
Age (yrl
30 to 49 1.1 1.5 26.7
50 to 59 2.2 3. 1 29.0
60 to 69 30 55 45.5
DBP (rnmHg)
90 10 104 1 :; 2.2 3 1 8
105 to 11 4 2.4 3.7 35. 1
2: 11 5 35 6.4 45.3
All patients 1.9 29 34.5
DBP = dtaxtolrc blood prcv-urc.%! = percent reduction. RC = referred care
SC = stepped care
From HDFPStudy (121
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trials (15,16). Effective blood pressure control. surgical cor-
rection of appropriate atherosclerotic lesions and judicious
use of antiplatelet and anticoagulant agents should decrease
the incidence of stroke in this high risk group of patients.
Hypertension and Recurrent Stroke
Role of antihypertensive treatment. Hypertensive stroke
survivors are at increased risk for the development of re-
current cerebral infarction. Successful antihypertensive ther-
apy appears to decrease this risk. Marshall (17) compared
the course of treated and untreated hypertensive stroke sur-
vivors retrospectively in 1964. Thirty-nine patients with a
diastolic blood pressure of 110 mm Hg or greater were given
antihypertensive medications with a goal to reduce diastolic
blood pressure to 100 to 110 mm Hg. Eight nonfatal and
two fatal cerebrovascular events occurred in a 3 year follow-
up period. This compared favorably with findings in a group
of 42 untreated stroke survivors followed up by Marshall
and Kaeser (18) in 1961. Twenty-two nonfatal and five fatal
cerebrovascular events occurred in this group of patients
during a 117 week period of observation.
Beevers et al. (19) followed up 162 hypertensive stroke
survivors for periods of up to 12 years with an average
follow-up time of 48 months. Antihypertensive medication
was given to all patients, and the adequacy of blood pressure
control was evaluated at subsequent follow-up visits. Blood
pressure control was said to be "good" if the standing
diastolic blood pressure was less than 100 mm Hg, "fair"
if between 100 and 109 mm Hg and' 'poor" if greater than
110 mm Hg. Patients with well controlled hypertension had
a 16% incidence rate of recurrent stroke compared with 32%
for patients whose hypertension was under fair control and
55% when hypertension was poorly controlled. Carter (20)
conducted a randomized trial in 97 stroke survivors whose
diastolic blood pressure was 110 mm Hg or greater. Anti-
hypertensive medications were given to half of the patients
with a goal diastolic blood pressure reduction between 90
and 100 mm Hg. After 5 years of follow-up, 10 untreated
and 3 treated patients experienced fatal cerebral infarction
or hemorrhage. These studies seem to indicate that effective
antihypertensive therapy reduces stroke incidence in mod-
erately or severely hypertensive survivors of stroke.
A prospective, placebo-controlled double-blind study of
patients with established cerebrovascular disease and mild
to moderate hypertension was conducted by the Hyperten-
sion-Stroke Cooperative Study Group beginning in 1966
(21). Patients with a recumbent blood pressure of 140 to
220 mm Hg systolic and 90 to 115 mm Hg diastolic were
randomized to placebo or active drug treatment. Active drug
therapy consisted of a combination of 10 mg of methy-
clothiazide and I mg of deserpidine in 233 patients; 219
patients received placebo. The average baseline blood pres-
sure of 167/100 mm Hg fell by 26.3/13.3 mm Hg in the
drug-treated group. There was a small, but statistically In-
significant reduction in fatal and nonfatal strokes in the drug-
treated group with 37 strokes occurring in 233 drug-treated
patients and 42 strokes occurring In 219 placebo-treated
patients. A statistically significant reduction in the occur-
rence of congestive heart failure was noted in the drug-
treated patients. Because treatment of mild hypertension did
not increase the risk of recurrent cerebral infarction and
decreased the incidence of congestive heart failure, the study
group advocated antihypertensive therapy for stroke survi-
vors with mild to moderate hypertension.
Decreasing incidence of stroke. Successful manage-
ment of asymptomatic patients with hypertension and of
hypertensive patients with established cerebrovascular dis-
ease has undoubtedly contributed to the decreased incidence
of stroke. Stroke incidence has progressively declined in
the population of Rochester, Minnesota In the era of anti-
hypertensive therapy (22). The age- and sex-adjusted in-
cidence for cerebral infarction of 159 per 100,000 popu-
lation from 1945 to 1949 decreased to 107 per 100,000 from
1965 through 1969. This reduction appears to be acceler-
ating as the incidence from 1970 to 1974 fell to 83 per
100,000 population, a reduction of 22% from the previous
5 year period of observation. According to national statis-
tics, the incidence of fatal strokes in the United States has
decreased 45% in the last 10 years. Potentially, this trend
in reduction of stroke rate will continue as more patients
with mild hypertension are given antihypertensive therapy.
Antihypertensive Therapy in Patients With
Established Cerebrovascular Disease
Acute Cerebral Infarction or
Intracranial Hemorrhage
Cerebral infarction. The use of hypertensive agents is
somewhat controversial during the acute or evolving phase
of stroke, and differs in patients with cerebral infarction and
intracranial hemorrhage (23). Mildly hypertensive patients
(diastolic blood pressure 110 mm Hg or less) should prob-
ably be left untreated during the evolving phase of athero-
thrombotic brain infarction and for 3 weeks after a com-
pleted stroke. Moderate and severe hypertension should be
treated with oral agents provided that the patient can swal-
low. Blood pressure should be reduced to approximately
160/100 mm Hg for the first 3 weeks after the acute event
and to clearly normotensive levels thereafter. The approach
is similar to that outlined subsequently for patients with
transient ischemic attacks or remote cerebral infarction with
similar precautions regarding agents that cause orthostatic
hypotension (Table 3).
Severely hypertensive patients (blood pressure > 240/
140 mm Hg) and patients who cannot swallow require in-
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Agents of
Choice
Agents to
AVOId if
Possible
Blood Pressure Reduction
Goal Rate
Acute cerebral
infarcuon
Intracranial
hemorrhage
Remote cerebral
infarction
Diuretics
Beta-receptor
blockers
Methyldopa
Clonidine
Hydralazine
Sodium nitro-
prusside I.V.
Tnmethaphan I.V.
Diuretics
Beta-receptor
blockers
Methyldopa
Clorudine
Hydralazine
Prazosm
Diazoxide
Pargyline
Guanethidine
Reserpine
Methyldopa
Diazoxide
Prazosin
Guanethidine
Pargyline
160/110 mm Hg
Normotensive or
mildly
hypotensive levels
Normotensive levels
Over 24 to 48 hours*
Over 30 to 60
rrnnutes . observing
neurologic signs
Slowly. with dose
increments every 6
to 8 week>
"Panents WIth severe hypertension (blood pressure > 240/ 140 mm Hg) should miually have blood pres-ure reduced to 1701110 mm Hg over 30 to 60 nunute-,
I V = Intravenously
travenous agents. For this purpose, sodium nitroprusside is
the safest agent. Methyldopa and reserpine should be avoided
because they can confuse the neurologic evaluation as a
result of their sedative properties. Even small intermittent
doses of diazoxide may reduce blood pressure abruptly and
unfavorably, and alter cerebrovascular hemodynamics. Pa-
tients with brain-stem infarction are often severely hyper-
tensive. In these patients, a trial of blood pressure reduction
with sodium nitroprusside over a period of 30 to 60 minutes
is reasonable with close observation for changing neurologic
signs.
Intracranial hemorrhage. A trial of blood pressure re-
duction with sodium nitroprusside is also indicated in pa-
tients with intraparenchymal or subarachnoid hemorrhage.
Blood pressure should be reduced to normotensive or mildly
hypotensive levels over a period of 30 to 60 minutes by
titrating the dose of sodium nitroprusside. During this time,
the neurologic status of the patient should be closely eval-
uated. If there is evidence of neurologic deterioration. the
dosage of sodium nitroprusside can be decreased and blood
pressure will rapidly rise. There is concern that lower blood
pressure may promote cerebral ischemia because of im-
pairment in cerebral blood blow autoregulation that occurs
in both severe hypertension and stroke (24,25). Most neu-
rosurgeons prefer a relatively vigorous blood pressure re-
duction when there is active intracranial bleeding. Elec-
troencephalographic evidence of increasing brain ischemia
during the course of antihypertensive therapy In patients
undergoing repair of Intracranial aneurysms is lacking (26).
The poor prognosis for patients with hypertensive intracere-
bral hemorrhage makes a controlled trial of antihypertensive
therapy in this setting difficult to evaluate. Guidelines for
the management of patients with acute cerebral infarction
and intracranial hemorrhage are provided in Table 3.
Transient Ischemic Attacks and Remote
Cerebral Infarction
The fear that antihypertensive therapy will precipitate
cerebral ischemia and infarction in patients with established
cerebrovascular disease has not been supported by longi-
tudinal studies (13,17 ,19- 21). The majority of patients tol-
erate normotensive blood pressure levels well, with the pos-
sible exception of patients with lacunar infarction. These
small cystic areas of infarction caused by thrombosis or
hemorrhage from arterioles, particularly the lenticulo-
striates, are peculiar to the hypertensive state (27). Neu-
rologic deterioration may occur in patients with progressive
motor rigidity or multiinfarct dementia when blood pressure
is reduced. However. antihypertensive therapy offers the
only possibility of preventing progression of their small
vessel disease and is indicated in the majority of patients
with lacunar syndromes. If antihypertensive therapy is poorly
tolerated, treatment can be modified or abandoned.
Stepped care treatment approach. A stepped care ap-
proach to therapy that starts with oral administration of
diuretic drugs is useful in this group of patients, and pro-
ceeds much as it does in patients with hypertension who
have no evidence of cerebrovascular disease (Table 4) . Re-
duction of blood pressure should be gradual with dose in-
crements occurring at fairly long intervals (approximately
6 to 8 weeks). Drugs with the propensity to cause orthostatic
hypotension (prazosin, guanethidine. bethanidine and par-
gyline) should be avoided. Beta-receptor blocking agents
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Table 4. A Stepped Care Approach in the Medical Treatment
of Hypertension
Step I: Oral diuretic drug (25 to 50 109 hydrochlorothiazide
or its equivalent)
Step 2: Addition of an adrenergic inhibitor
Beta-receptor blocker (40 to 480 109 propranolol or ItS
equivalent)
Alpha, agonists
Methyldopa (250 to 2000 109 )
Clonidme (0 2 to 1.2 109 )
Alpha-receptor blocker
Prazosin (2 to 20 mg)*
Step 3. Addition of a vasodilator
Hydralazine (20 to 300 109)
' May be used as an alternative 10 hydral azine In step 3 In asymptomatic patients
are preferred for the second step of therapy because of their
relative lack of side effects. The large incidence of death
related to coronary artery disease in patients with cerebro-
vascular disease is further impetus to the use of beta-receptor
blockers in this group of patients. Hydralazine is the pre-
ferred third step of therapy in patients whose hypertension
is poorly controlled with diuretic drugs and beta-receptor
blockers. This drug is particularly useful in elderly patients
with isolated systolic hypertension for whom it may be used
as a second step agent (28).
Guidelines for the use of antihypertensive agents in pa-
tients with cerebrovasculardisease, either transient ischemic
attacks or remote cerebral infarction, are provided in Table
3. Elderly patients may be more sensitive to drug-related
side effects, and therapy should commence with the smallest
doses of appropriate agents. Increments in dosage or ad-
dition of new drugs should be made at intervals of no less
than every 6 to 8 weeks.
Conclusion
Hypertension accelerates the atherogenic process and is
the majorcorrectable risk factor in the development of stroke.
Treatment of hypertension has been shown to reduce the
incidence of both primary and recurrent stroke. Elderly pa-
tients and patients with mild hypertension appear to benefit
from antihypertensive therapy. A trial of antihypertensive
therapy using an infusion of sodium nitroprusside is indi-
cated during the acute phase of intracranial hemorrhage.
Mild hypertension may be left untreated in the evolving or
acute phase of nonhemorrhagic brain infarction. Effective
antihypertensive therapy, antiplatelet therapy and surgical
correction of accessible carotid artery lesions for patients
with transient ischemic attacks should continue the trend of
decreasing mortality from cerebrovascular disease in the
United States.
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